ALK-Abelló A/S's latest marketcap:
As of 07/05/2025, ALK-Abelló A/S's market capitalization has reached $6.5 B. According to our data, ALK-Abelló A/S is the 2742th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 6.5 B |
| Revenue (ttm) | 873.01 M |
| Net Income (ttm) | 143.31 M |
| Shares Out | 0 |
| EPS (ttm) | 0.64 |
| Forward PE | 33.49 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/21/2025 |
ALK-Abelló A/S's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | £6.5 B | 22.16% | 2742 |
| 12/30/2024 | £3.91 B | 50.18% | 3043 |
| 12/29/2023 | £2.61 B | 2.98% | 3974 |
| 12/30/2022 | £2.53 B | -40.43% | 3970 |
| 12/30/2021 | £4.25 B | 28.17% | 2872 |
| 12/30/2020 | £3.31 B | 62.88% | 3052 |
| 12/30/2019 | £2.03 B | 60.49% | 3770 |
| 12/28/2018 | £1.27 B | 45.9% | 4592 |
| 12/29/2017 | £869.08 M | -16.45% | 6455 |
| 12/30/2016 | £1.04 B | 23.79% | 5452 |
Company Profile
About ALK-Abelló A/S
ALK-Abelló A/S is a global leader in allergy solutions, operating across Europe, North America, and internationally. Founded in 1923 and headquartered in Hørsholm, Denmark, the company specializes in innovative treatments for allergic conditions.
Product Portfolio
The company offers a range of allergy immunotherapy products, including:
- GRAZAX/GRASTEK – Grass pollen allergy tablet
- RAGWITEK/RAGWIZAX – Ragweed allergy treatment
- ACARIZAX/ODACTRA – House dust mite allergy therapy
- MITICURE – Treatment for house dust mite-induced allergy
- CEDARCURE – Japanese cedar pollen allergy solution
- ITULAZAX/ITULATEK – Food allergy immunotherapy
Treatment Solutions
ALK-Abelló provides allergy immunotherapy in multiple forms:
- Injections
- Sublingual drops
- Tablets
These treatments target allergies caused by house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food allergens.
Consumer Healthcare & Digital Solutions
The company offers a Digital eco-system, a platform designed to:
- Engage with allergy sufferers throughout their treatment journey
- Provide tools and e-commerce solutions for support and relief
- Simplify access to allergy immunotherapy treatments
Diagnostic & Emergency Solutions
ALK-Abelló also delivers:
- Diagnostic allergy testing via skin prick or blood tests
- Emergency treatments such as adrenaline injections for life-threatening allergic reactions (anaphylaxis)
Strategic Collaborations
The company partners with Torii Pharmaceutical Co., Ltd. to develop and distribute key allergy treatments, including GRAZAX, CEDARCURE, and MITICURE.
Frequently Asked Questions
-
What is ALK-Abelló A/S's (LON-0OIR) current market cap?As of 07/05/2025, ALK-Abelló A/S (including the parent company, if applicable) has an estimated market capitalization of $6.5 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does ALK-Abelló A/S (LON-0OIR) rank globally by market cap?ALK-Abelló A/S global market capitalization ranking is approximately 2742 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.